Meanwhile, the FDA granted accelerated approval to PD-1 inhibitors (Keytruda, pembrolizumab) combined with trastuzumab and chemotherapy for the first-line therapy of HER2-positive advanced gastric carcinoma in accordance with the mid-term data of the KEYNOTE-811 trial (30). Here, ERBB2 is linked to gastric carcinoma.